Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05669599 · ClinicalTrials.gov registry record · Phase 2
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 592
- Enrollment target
NCT05669599 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 592 participants.
The verdict
NCT05669599, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 592 participants
- Enrollment target
Study Summary
The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overweight or obesity with Type 2 diabetes mellitus (Cohort B).
Interventions
- DRUG Placebo
- BIOLOGICAL Maridebart Cafraglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 592 participants |
| Start Date | 2023-01-18 |
| Est. Completion | 2025-12-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05669599
The ClinicalTrials.gov registry entry for NCT05669599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 592 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05669599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05669599 about?
NCT05669599 is a clinical study titled "Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus". The study aims to compare and assess the dose response of 3 selected doses of maridebart cafraglutide compared with placebo, on inducing and maintaining weight loss from baseline at Week 52 in participants with overweight or obesity without diabetes mellitus (Cohort A) and in participants with overw...
What is the current status of trial NCT05669599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 592 participants. The study started on 2023-01-18. Estimated completion is 2025-12-16.
What interventions are being tested in trial NCT05669599?
The interventions under investigation include: Placebo (DRUG), Maridebart Cafraglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT05669599?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.